Pharmaceutical policy and market trends are shifting. The Trump administration finalizes Medicare Part D Most Favored Nation (MFN) rule, setting precedent for presidential drug price negotiations. Pfizer's MFN deal, while not altering operations, creates political and pricing implications. Discussions about drug price transparency and FDA direct-to-consumer advertising regulations are heating up as industry stakeholders prepare for new compliance and commercial challenges.